Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 827

1.

Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.

Kessler D, Burns A, Tallon D, Lewis G, MacNeill S, Round J, Hollingworth W, Chew-Graham C, Anderson I, Campbell J, Dickens C, Macleod U, Gilbody S, Davies S, Peters TJ, Wiles N.

Health Technol Assess. 2018 Nov;22(63):1-136. doi: 10.3310/hta22630.

2.

Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).

Kessler DS, MacNeill SJ, Tallon D, Lewis G, Peters TJ, Hollingworth W, Round J, Burns A, Chew-Graham CA, Anderson IM, Shepherd T, Campbell J, Dickens CM, Carter M, Jenkinson C, Macleod U, Gibson H, Davies S, Wiles NJ.

BMJ. 2018 Oct 31;363:k4218. doi: 10.1136/bmj.k4218. Erratum in: BMJ. 2018 Nov 15;363:k4691.

3.

Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial.

Tallon D, Wiles N, Campbell J, Chew-Graham C, Dickens C, Macleod U, Peters TJ, Lewis G, Anderson IM, Gilbody S, Hollingworth W, Davies S, Kessler D.

Trials. 2016 Feb 3;17:66. doi: 10.1186/s13063-016-1199-2.

4.

Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial.

Wiles N, Thomas L, Abel A, Barnes M, Carroll F, Ridgway N, Sherlock S, Turner N, Button K, Odondi L, Metcalfe C, Owen-Smith A, Campbell J, Garland A, Hollinghurst S, Jerrom B, Kessler D, Kuyken W, Morrison J, Turner K, Williams C, Peters T, Lewis G.

Health Technol Assess. 2014 May;18(31):1-167, vii-viii. doi: 10.3310/hta18310.

5.

Antidepressant treatment with sertraline for adults with depressive symptoms in primary care: the PANDA research programme including RCT.

Duffy L, Lewis G, Ades A, Araya R, Bone J, Brabyn S, Button K, Churchill R, Croudace T, Derrick C, Dixon P, Dowrick C, Fawsitt C, Fusco L, Gilbody S, Harmer C, Hobbs C, Hollingworth W, Jones V, Kendrick T, Kessler D, Khan N, Kounali D, Lanham P, Malpass A, Munafo M, Pervin J, Peters T, Riozzie D, Robinson J, Salaminios G, Sharp D, Thom H, Thomas L, Welton N, Wiles N, Woodhouse R, Lewis G.

Southampton (UK): NIHR Journals Library; 2019 Dec.

6.

Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.

Edwards SJ, Hamilton V, Nherera L, Trevor N.

Health Technol Assess. 2013 Nov;17(54):1-190. doi: 10.3310/hta17540. Review.

7.

A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.

Salaminios G, Duffy L, Ades A, Araya R, Button KS, Churchill R, Croudace T, Derrick C, Dixon P, Dowrick C, Gilbody S, Hollingworth W, Jones V, Kendrick T, Kessler D, Kounali D, Lanham P, Malpass A, Peters TJ, Riozzie D, Robinson J, Sharp D, Thomas L, Welton NJ, Wiles N, Lewis G.

Trials. 2017 Oct 24;18(1):496. doi: 10.1186/s13063-017-2253-4.

8.

Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.

Kendrick T, Chatwin J, Dowrick C, Tylee A, Morriss R, Peveler R, Leese M, McCrone P, Harris T, Moore M, Byng R, Brown G, Barthel S, Mander H, Ring A, Kelly V, Wallace V, Gabbay M, Craig T, Mann A.

Health Technol Assess. 2009 Apr;13(22):iii-iv, ix-xi, 1-159. doi: 10.3310/hta13220.

9.

The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.

Lewis G, Duffy L, Ades A, Amos R, Araya R, Brabyn S, Button KS, Churchill R, Derrick C, Dowrick C, Gilbody S, Fawsitt C, Hollingworth W, Jones V, Kendrick T, Kessler D, Kounali D, Khan N, Lanham P, Pervin J, Peters TJ, Riozzie D, Salaminios G, Thomas L, Welton NJ, Wiles N, Woodhouse R, Lewis G.

Lancet Psychiatry. 2019 Nov;6(11):903-914. doi: 10.1016/S2215-0366(19)30366-9. Epub 2019 Sep 19.

10.

Cost and Outcome of BehaviouRal Activation (COBRA): a randomised controlled trial of behavioural activation versus cognitive-behavioural therapy for depression.

Richards DA, Rhodes S, Ekers D, McMillan D, Taylor RS, Byford S, Barrett B, Finning K, Ganguli P, Warren F, Farrand P, Gilbody S, Kuyken W, O'Mahen H, Watkins E, Wright K, Reed N, Fletcher E, Hollon SD, Moore L, Backhouse A, Farrow C, Garry J, Kemp D, Plummer F, Warner F, Woodhouse R.

Health Technol Assess. 2017 Aug;21(46):1-366. doi: 10.3310/hta21460.

11.

Manualised cognitive-behavioural therapy in treating depression in advanced cancer: the CanTalk RCT.

Serfaty M, King M, Nazareth I, Moorey S, Aspden T, Tookman A, Mannix K, Gola A, Davis S, Wood J, Jones L.

Health Technol Assess. 2019 May;23(19):1-106. doi: 10.3310/hta23190.

12.

CollAborative care for Screen-Positive EldeRs with major depression (CASPER plus): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness.

Bosanquet K, Adamson J, Atherton K, Bailey D, Baxter C, Beresford-Dent J, Birtwistle J, Chew-Graham C, Clare E, Delgadillo J, Ekers D, Foster D, Gabe R, Gascoyne S, Haley L, Hamilton J, Hargate R, Hewitt C, Holmes J, Keding A, Lewis H, McMillan D, Meer S, Mitchell N, Nutbrown S, Overend K, Parrott S, Pervin J, Richards DA, Spilsbury K, Torgerson D, Traviss-Turner G, Trépel D, Woodhouse R, Gilbody S.

Health Technol Assess. 2017 Nov;21(67):1-252. doi: 10.3310/hta21670.

13.

Lamotrigine for people with borderline personality disorder: a RCT.

Crawford MJ, Sanatinia R, Barrett B, Cunningham G, Dale O, Ganguli P, Lawrence-Smith G, Leeson VC, Lemonsky F, Lykomitrou-Matthews G, Montgomery A, Morriss R, Munjiza J, Paton C, Skorodzien I, Singh V, Tan W, Tyrer P, Reilly JG.

Health Technol Assess. 2018 Apr;22(17):1-68. doi: 10.3310/hta22170.

14.

A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: the RESPOND trial.

Sharp DJ, Chew-Graham C, Tylee A, Lewis G, Howard L, Anderson I, Abel K, Turner KM, Hollinghurst SP, Tallon D, McCarthy A, Peters TJ.

Health Technol Assess. 2010 Sep;14(43):iii-iv, ix-xi, 1-153. doi: 10.3310/hta14430.

15.

CollAborative care and active surveillance for Screen-Positive EldeRs with subthreshold depression (CASPER): a multicentred randomised controlled trial of clinical effectiveness and cost-effectiveness.

Lewis H, Adamson J, Atherton K, Bailey D, Birtwistle J, Bosanquet K, Clare E, Delgadillo J, Ekers D, Foster D, Gabe R, Gascoyne S, Haley L, Hargate R, Hewitt C, Holmes J, Keding A, Lilley-Kelly A, Maya J, McMillan D, Meer S, Meredith J, Mitchell N, Nutbrown S, Overend K, Pasterfield M, Richards D, Spilsbury K, Torgerson D, Traviss-Turner G, Trépel D, Woodhouse R, Ziegler F, Gilbody S.

Health Technol Assess. 2017 Feb;21(8):1-196. doi: 10.3310/hta21080.

16.

Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.

Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A.

Health Technol Assess. 2013 Feb;17(7):1-166. doi: 10.3310/hta17070.

17.

Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial.

Wiles NJ, Thomas L, Turner N, Garfield K, Kounali D, Campbell J, Kessler D, Kuyken W, Lewis G, Morrison J, Williams C, Peters TJ, Hollinghurst S.

Lancet Psychiatry. 2016 Feb;3(2):137-44. doi: 10.1016/S2215-0366(15)00495-2. Epub 2016 Jan 7.

18.

A pragmatic randomised controlled trial to evaluate the cost-effectiveness of a physical activity intervention as a treatment for depression: the treating depression with physical activity (TREAD) trial.

Chalder M, Wiles NJ, Campbell J, Hollinghurst SP, Searle A, Haase AM, Taylor AH, Fox KR, Baxter H, Davis M, Thorp H, Winder R, Wright C, Calnan M, Lawlor DA, Peters TJ, Sharp DJ, Turner KM, Montgomery AA, Lewis G.

Health Technol Assess. 2012;16(10):1-164, iii-iv. doi: 10.3310/hta16100.

20.

Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning.

McMurran M, Crawford MJ, Reilly J, Delport J, McCrone P, Whitham D, Tan W, Duggan C, Montgomery AA, Williams HC, Adams CE, Jin H, Lewis M, Day F.

Health Technol Assess. 2016 Jul;20(52):1-250. doi: 10.3310/hta20520.

Supplemental Content

Support Center